Qrxpharma Ltd (QRXPF) 0.0010 $QRXPF IMPORTANT INVESTOR

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Qrxpharma Ltd (QRXPF) 0.0010 $QRXPF

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against QRx Pharma, Ltd. on Behalf of Investors
BusinessWire - Thu Aug 13, 8:53PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by QRx Pharma, Ltd. ("QRx" or the "Company" (OTC: QRXPY) (OTC: QRXPF). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.

GPM Announces the Filing of a Securities Class Action on Behalf of QRx Pharma, Ltd. Investors
BusinessWire - Wed Aug 12, 10:05AM CDT
Glancy Prongay & Murray LLP ("GPM" announces the filing of a class action lawsuit on behalf of investors of QRx Pharma, Ltd. ("QRX" or the "Company" (OTC Ticker: QRXPY; QRXPF), who purchased shares between January 24, 2011 and April 23, 2014, inclusive (the "Class Period" . QRX investors have until August 21, 2015 to file a motion to serve as lead plaintiff in the class action.

EQUITY ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against QRx Pharma, Ltd. -- QRXPY, QRXPF
GlobeNewswire - Thu Jul 30, 3:37PM CDT
The Rosen Law Firm, a global investor rights law firm, announces that the filing of a class action lawsuit on behalf of purchasers of QRx Pharma, Ltd. (OTC:QRXPY) (OTC:QRXPF) American Depository Shares from January 24, 2011 through April 23, 2014, both dates inclusive (the "Class Period" . The lawsuit seeks to recover damages for QRx Pharma investors under the federal securities laws.

ALERT: The Rosen Law Firm Reminds QRx Pharma, Ltd. Investors of the Important Deadline in the Class Action - QRXPY, QRXPF
BusinessWire - Fri Jul 10, 2:30PM CDT
The Rosen Law Firm, a global investor rights law firm, reminds purchasers of QRx Pharma, Ltd. (OTC:QRXPY, QRXPF) American Depository Shares from January 24, 2011 through April 23, 2014, both dates inclusive (the "Class Period" of the important August 24, 2015 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for QRx Pharma investors under the federal securities laws.

INVESTOR ALERT: Investigation of QRx Pharma, Ltd., Announced by Glancy Prongay & Murray LLP
BusinessWire - Mon Jul 06, 10:14AM CDT
Glancy Prongay & Murray LLP announces an investigation on behalf of investors of QRx Pharma, Ltd. ("QRx Pharma" or the "Company" (OTC Ticker: QRXPY; QRXPF) concerning whether the Company misled investors regarding the potential approval of its drug products. Glancy Prongay & Murray is preparing to file a complaint to recover damages on behalf of QRx Pharma investors, and investors are encouraged to contact the firm to discuss the matter.

EQUITY ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against QRx Pharma, Ltd.
BusinessWire - Mon Jun 29, 4:57PM CDT
The Rosen Law Firm, a global investor rights law firm, announces that the filing of a class action lawsuit on behalf of purchasers of QRx Pharma, Ltd. (OTC:QRXPY, QRXPF) American Depository Shares from January 24, 2011 through April 23, 2014, both dates inclusive (the "Class Period" . The lawsuit seeks to recover damages for QRx Pharma investors under the federal securities laws.

Hemorrhage Pipeline Review 2015 - 6 Companies & 9 Drug Profiles
M2 - Thu May 21, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vsfdh6/hemorrhage) has announced the addition of the "Hemorrhage - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemorrhage, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemorrhage and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cellphire, Inc. - Digna Biotech, S.L. - Haemostatix Ltd - QRxPharma Limited - Serendex Pharmaceuticals A/S - Thrombotargets Corporation Drug Profiles - DB-055 - eptacog alfa - PeproStat - Protein for Hematological Disorders, Dermatology, Shock and Injury - Q-8008 - Thrombosomes - TT-111 - TT-112 - V-0801 For more information visit http://www.researchandmarkets.com/research/vsfdh6/hemorrhage

Hemorrhage - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjlpxn/hemorrhage) has announced the addition of the "Hemorrhage - Pipeline Review, H2 2013" report to their offering. 'Hemorrhage - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemorrhage, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemorrhage. Hemorrhage - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - A snapshot of the global therapeutic scenario for Hemorrhage. - A review of the Hemorrhage products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemorrhage pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hemorrhage. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hemorrhage pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Grifols, S.A. - Digna Biotech, S.L. - Thrombotargets Corporation - QRxPharma Limited For more information visit http://www.researchandmarkets.com/research/fjlpxn/hemorrhage

Parkinson's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/7k9xvt/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 169 companies are cited in this text including: - Amicus Therapeutics, Inc. - AstraZeneca PLC - Bial - Portela & Ca, S.A. - Calico LLC - Cardax Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - GlaxoSmithKline plc - GliaCure Inc. - H. Lundbeck A/S - Io Therapeutics, Inc. - Iproteos S.L. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Medeia Therapeutics Ltd. - Motac Neuroscience Ltd - Netherlands Translational Research Center B.V. - nLife Therapeutics, S.L. - Novartis AG - OPKO Health, Inc. - Orion Oyj - Peptron, Inc. - Pfizer Inc. - QR Pharma, Inc. - QRxPharma Limited - Raptor Pharmaceuticals Corp. - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Stelic Institute & Co. - Sumitomo Dainippon Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/7k9xvt/parkinsons
RPTP: 5.66 (-0.03), KNMD: (), OPK: 9.86 (+0.01), PFE: 35.74 (-0.12), AZN: 30.29 (+0.20), GSK: 43.57 (-0.08), FOLD: 6.10 (+0.42), NVS: 82.09 (+0.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 423

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 346

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 344

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 220

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 477

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 103

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 102

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 378

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 323

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

Apple Inc. Announces Record Q4 Results and Product Launches

Updated Category News Views 236

Apple Achieves Remarkable Fourth Quarter Results Apple Inc. has announced its financial performance for the fourth quarter of its fiscal year 2024, showcasing stellar results that reflect the company's growth and expansion in the tech industry. The tech giant reported quarterly revenue hitting a staggering $94.9 billion, which represents a 6% increase compared to the...

Continue Reading
China-Russia Culture Fair Boosts Jiamusi, Heilongjiang

Updated Category News Views 100

Jiamusi: A Cultural Crossroad in Northeast China Imagine this: Jiamusi, nestled in the embrace of Heilongjiang Province, stepping into the spotlight as it co-hosts the 16th China-Russia culture fair. This northeast city isn't just another dot on the map. It's gearing up to be a hub of cultural buzz, packed with ties that go beyond borders. From July through September,...

Continue Reading
Unlocking Sustainability in Broadband Using Existing Networks

Updated Category News Views 176

Unlocking Sustainability in Broadband Using Existing Networks LUND, Sweden — InCoax Networks has introduced a groundbreaking whitepaper addressing the modernization of broadband infrastructure in multi-dwelling units (MDUs). This initiative is not only cost-effective but also significantly improves the environmental impact associated with deploying broadband services....

Continue Reading
Interlink Electronics Secures NASA Grant for Air Quality Solutions

Updated Category News Views 174

Interlink Electronics Receives Significant Funding from NASA Recognizes Company's leading position in gas sensor research and commercialization Interlink Electronics, Inc. (NASDAQ: LINK), a premier provider of innovative sensors and electronic solutions, has received a significant boost with a $150,000 award from NASA. This funding is designated for the development of...

Continue Reading
Burford Capital Set to Reveal 3Q24 Financial Insights Soon

Updated Category News Views 154

Burford Capital Set to Release 3Q24 Financial Results Burford Capital Limited, renowned for its leadership in finance and asset management focused on legal services, has announced the date for its financial results. The firm is poised to share critical insights regarding its performance for the three and nine months ending September 30, 2024. Details of the Financial...

Continue Reading